Last updated on February 2018

HuMax-AXL-ADC Safety Study in Patients With Solid Tumors


Brief description of study

The purpose of the trial is to establish the tolerability of HuMax-AXL-ADC in a mixed population of patients with specified solid tumors

Detailed Study Description

The trial consists of two parts; a dose escalation part (phase I, first in- human (FIH)) and an expansion part (phase IIa).

The dose escalation part has two dose escalation arms: the first arm investigates a once every 3 weeks (1Q3W) dose schedule and the second one investigates a three administrations over 4 weeks (3Q4W) dose schedule.

The Expansion part of the trial, will further explore the recommended phase 2 dose of HuMax-AXL-ADC as determined in Part 1

Clinical Study Identifier: NCT02988817

Contact Investigators or Research Sites near you

Start Over

Ignace Vergote, Professor

Universitair Ziekenhuizen Leuven
Leuven, Belgium
  Connect »

Ulrik Lassen, MD

Rigshospitalet, Copenhagen University Hospital
Copenhagen, Denmark
  Connect »

Juanita Lopez, MD

The Royal Marsden NHS Foundation Trust
United Kingdom, United Kingdom
  Connect »

Suresh Ramalingham, MD

Emory University School of Medicine, Winship Cancer Institute
Atlanta, GA United States
  Connect »

Fiona Thistlethwaite, MD

The Christie NHS Foundation Trust Clinical Trials Unit
Manchester, United Kingdom
  Connect »

Yvette Drew, MD

Sir Bobby Robson Clinical Trials Unit at the Northern Centre for Cancer Care, Freeman Hospital
Newcastle, United Kingdom
  Connect »